All Topics
All Topics
Technology
Technology
AI
AI
Business
Business
Entertainment
Entertainment
News
News
Programming
Programming
Security
Security
Science
Science
Design
Design
Environment
Environment
Finance
Finance
Crypto
Crypto
Politics
Politics
Sports
Sports
Education
Education
Gaming
Gaming
Art
Art
Music
Music
Health
Health
Books
Books
Food
Food
Travel
Travel
Personal
Personal
Bluesky
Twitter

Norway's Crown Princess Mette-Marit placed on lung transplant list due to worsening pulmonary fibrosis

By

Leer en español

16d ago· 2 min readenNews

Summary

Norway's Crown Princess Mette-Marit, 52, has been placed on a lung transplant list due to worsening pulmonary fibrosis, a progressive and incurable lung disease she was diagnosed with in 2018. The Royal Court announced Friday that she will suspend her official duties, with no further medical updates until after the transplant. A longer rehabilitation period will follow her hospital discharge. Norway's public broadcaster reported a significant deterioration in her condition over the past six months.

Source

bskyNorway's Crown Princess Mette-Marit placed on lung transplant list due to worsening pulmonary fibrosisbit.ly

Key quotes

· 4 pulled
Norway's Crown Princess Mette-Marit has been placed on a lung transplant list, Norway's Royal Court said in a statement.
Mette-Marit, 52, was diagnosed in 2018 with pulmonary fibrosis, a progressive disease that damages and scars lung tissue.
She will suspend her official duties and a new medical update will only be provided after the lung transplant has taken place, the statement said Friday.
After discharge from the hospital, 'there will be a longer period of rehabilitation.'
Snippet from the RSS feed
Norway’s Crown Princess Mette-Marit has been placed on a lung transplant list due to worsening pulmonary fibrosis. Diagnosed in 2018, the disease damages and scars lung tissue, causing serious breathing problems. The Royal Court announced Friday that she

You might also wanna read

Comments

Sign in to join the conversation.

No comments yet. Be the first.